FDA lays out a plan to step up PRD drug development
By Mari Serebrov
Thursday, July 10, 2014
Keeping up with its obligations under the FDA Safety and Innovation Act (FDASIA), the FDA issued its strategic plan for accelerating the development of drugs and medical devices to treat rare diseases in children.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.